English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Chronic inflammation in the kidneys and vascular wall is a major contributor to hypertension. However, the stimuli and cellular mechanisms responsible for such inflammatory responses remain poorly defined. Inflammasomes are crucial initiators of sterile inflammation in other diseases such as rheumatoid arthritis and gout. These pattern recognition receptors detect host‐derived danger‐associated molecular patterns ( DAMPs ), such as microcrystals and reactive oxygen species, and respond by inducing activation of caspase‐1. Caspase‐1 then processes the cytokines pro‐ IL ‐1β and pro‐ IL ‐18 into their active forms thus triggering inflammation. While  IL ‐1β and  IL ‐18 are known to be elevated in hypertensive patients, no studies have examined whether this occurs downstream of inflammasome activation or whether inhibition of inflammasome and/or  IL ‐1β/ IL ‐18 signalling prevents hypertension. In this review, we will discuss some known actions of  IL ‐1β and  IL ‐18 on leukocyte and vessel wall function that could potentially underlie a prohypertensive role for these cytokines. We will describe the major classes of inflammasome‐activating  DAMPs  and present evidence that at least some of these are elevated in the setting of hypertension. Finally, we will provide information on drugs that are currently used to inhibit inflammasome/ IL ‐1β/ IL ‐18 signalling and how these might ultimately be used as therapeutic agents for the clinical management of hypertension.

IL ‐1β and IL ‐18: inflammatory markers or mediators of hypertension?